Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q1 2018 · 10-Q
Revenue—
Net Income-$3.76M-$3.76MN/M vs Q1 2017 EPS Diluted-$0.21-$0.21N/M vs Q1 2017 Operating Income-$7,806,000N/M Operating Cash Flow-$8,219,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
Free Cash Flowderived-$8,400,000N/M ended Mar 31, 2018 · filed May 8, 2018 · 38 d after period end